Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns?

J E Tyson, C Pedroza, J Langer, C Green, B Morris, D Stevenson, K P Van Meurs, W Oh, D Phelps, M O'Shea, G E McDavid, C Grisby, R Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, J E Tyson, C Pedroza, J Langer, C Green, B Morris, D Stevenson, K P Van Meurs, W Oh, D Phelps, M O'Shea, G E McDavid, C Grisby, R Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network

Abstract

Objective: Aggressive phototherapy (AgPT) is widely used and assumed to be safe and effective for even the most immature infants. We assessed whether the benefits and hazards for the smallest and sickest infants differed from those for other extremely low-birth-weight (ELBW; ≤ 1000 g) infants in our Neonatal Research Network trial, the only large trial of AgPT.

Study design: ELBW infants (n=1974) were randomized to AgPT or conservative phototherapy at age 12 to 36 h. The effect of AgPT on outcomes (death, impairment, profound impairment, death or impairment (primary outcome), and death or profound impairment) at 18 to 22 months of corrected age was related to BW stratum (501 to 750 g; 751 to 1000 g) and baseline severity of illness using multilevel regression equations. The probability of benefit and of harm was directly assessed with Bayesian analyses.

Result: Baseline illness severity was well characterized using mechanical ventilation and FiO(2) at 24 h age. Among mechanically ventilated infants ≤ 750 g BW (n=684), a reduction in impairment and in profound impairment was offset by higher mortality (P for interaction <0.05) with no significant effect on composite outcomes. Conservative Bayesian analyses of this subgroup identified a 99% (posterior) probability that AgPT increased mortality, a 97% probability that AgPT reduced impairment, and a 99% probability that AgPT reduced profound impairment.

Conclusion: Findings from the only large trial of AgPT suggest that AgPT may increase mortality while reducing impairment and profound impairment among the smallest and sickest infants. New approaches to reduce their serum bilirubin need development and rigorous testing.

Conflict of interest statement

The authors declare no other potential conflicts of interest.

References

    1. Lucey JF. Fetal infants: thoughts about what to do. Pediatrics. 2004;113(6):1819.
    1. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in ELBW infants. Pediatrics. 2003;112(4):773–779.
    1. Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O’Shea TM, et al. Aggressive vs. conservative phototherapy for infants with ELBW. N Engl J Med. 2008;359(18):1885–96.
    1. Brown AK, Kim MH, Wu PYK, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics. 1985;75(2 Pt 2):393–400.
    1. Lipsitz PJ, Gartner LM, Bryla DA. Neonatal and infant mortality in relation to phototherapy. Pediatrics. 1985;75(2 Pt 2):422–426.
    1. Maisels MJ. Chapter 22. Neonatal jaundice. In: Sinclair JC, Bracken MB, editors. Effective care of the newborn infant. Oxford, England: Oxford University Press; 1992. p. 532. Table 47.
    1. Maisels MJ. Neonatal hyperbilirubinemia. In: Klaus MH, Fanaroff AA, editors. Care of the high-risk neonate. 5. Philadelphia: W.B. Saunders; 2001. pp. 324–62.
    1. Gopinathan V, Miller NJ, Milner AD, Rice-Evans CA. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Letter. 1994;349(2):197–200.
    1. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043–1046.
    1. Tozzi E, Tozzi-Ciancarelli MG, Di Giulo A, D’Alfonso A, Farello G, Spennati GF, et al. In vitro and in vivo effects of erythrocyte phototherapy on newborns. Biol Neonate. 1989;56(4):204–209.
    1. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol. 2004;28(5):326–333.
    1. Roll EB, Christensen T. Formation of photoproducts and cytotoxicity of bilirubin irradiated with turquoise and blue phototherapy light. Acta Paediatr. 2005;94:1448–54.
    2. Acta Paediatr. 2005 Oct;94(10):1360–2.
    1. Wennberg RP. The blood-brain barrier and bilirubin encephalopathy. Cell Mol Neurobiol. 2000;20(1):97–109.
    1. Hansen TWR. Mechanisms of bilirubin toxicity: clinical implications. Clin Perinatol. 2002;29(4):765–778.
    1. Bender GJ, Cashore WJ, Oh W. Ontogeny of bilirubin-biimpairmentng capacity and the effect of clinical status in premature infants born at less than 1300 grams. Pediatrics. 2007;120(5):1067–1073.
    1. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. An introduction to Bayesian methods in health technology assessment. BMJ. 1999;319(7208):508–512.
    1. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ. 1995;311(7020):1621–1625.
    1. Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol. 2009;62(1):13–21.e5.
    1. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of ELBW infants <32 weeks’ gestation between 1993 and 1998. Pediatrics. 2005;116(3):635–643.
    1. Bayley N. Bayley Scales of infant development II. New York: Psychological Corporation; 1993.
    1. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214–223.
    1. Hack M, Taylor HG, Drotar D, Schluchter M, Cartar L, Wilson-Costello D, et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of ELBW children at school age. Pediatrics. 2005;116:333–41.
    1. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med. 2008;358(16):1672–81.
    1. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–6.
    1. Dixon DO, Simon R. Bayesian Subset Analysis. Biometrics. 1991;47(3):871–881.
    1. Sinclair JC, Haughton DE, Bracken MB, Horbar JD, Soll RF. Cochrane neonatal systematic reviews: a survey of the evidence for neonatal therapies. Clin Perinatol. 2003;30(2):285–304.
    1. Jones HE, Ohlssen DI, Neuenschwander B, Racine A, Branson M. Bayesian models for subgroup analysis in clinical trials. Clin Trials. 2011;8(2):129–43.
    1. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005;58:261–268.
    1. Silverman WA. Human experimentation in perinatology. Clin Perinatol. 1987;14:403–16.
    1. Kraemer HC, Frank E. Evaluation of comparative treatment trials. Assessing clinical benefits and risks for patients, rather than statistical effects on measures. JAMA. 2010;304(6):683–684.
    1. Oxman A, Guyatt G. Summarizing the evidence: when to believe a subgroup analysis. In: Guyatt G, Drummond R, editors. Users’ guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press; 2002. pp. 553–65.
    1. McGrayne SB. The theory that would not die. Yale University Press; New Haven: 2011.
    1. Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2(4):282–90.
    1. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification: Health Utilities Index Mark 2. Med Care. 1996;34(7):702–722.
    1. Saigal S, Stoskopf BL, Burrows E, Streiner DL, Rosenbaum PL. Stability of maternal preferences for pediatric health states in the perinatal period and 1 year later. Arch Pediatr Adolesc Med. 2003;157(3):261–269.
    1. Oh W, Stevenson DK, Tyson JE, Morris BH, Ahlfors CE, Bender GJ, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in ELBW infants. Acta Paediatr. 2010;99(5):673–8.
    1. Watchko JF, Maisels MJ. Enduring controversies in the management of hyperbilirubinemia in preterm infants. Sem Fetal Neonatal Med. 2010;15:136–40.
    1. Wong RJ, Bhutani VK, Vreman HJ, Stevenson DK. Tin mesoporphyrin for the prevention of severe neonatal hyperbilirubinemia. Neo Reviews. 2007;8(2):77–84.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다